News
AIM ImmunoTech (AIM) announced that the first ... DURIPANC is an investigator-initiated, exploratory, open-label, single-center study in the Netherlands at the Erasmus Medical Center.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback